- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:06 | OSR Holdings licenses VXM01 to BCME for up to $815M in milestones | 5 | Investing.com | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 16:02 | OSR Holdings, Inc.: OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe | 289 | ACCESS Newswire | Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings... ► Artikel lesen | |
| 22.04. | Yeiseok Kim wird neuer Chief Operating Officer bei OSR Holdings | - | Investing.com Deutsch | ||
| 22.04. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | OSR Holdings, Inc.: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note | 327 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White... ► Artikel lesen | |
| 02.04. | OSR Holdings und BCM Europe: Neue Lizenzvereinbarung für VXM01 sichert Zahlungen von bis zu 815 Mio. $ | 2 | Investing.com Deutsch | ||
| 02.04. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | OSR Holdings, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | OSR Holdings, Inc.: OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026 | 169 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today... ► Artikel lesen | |
| 27.03. | Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target | 347 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price... ► Artikel lesen | |
| 23.03. | OSR Holdings, Inc.: OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level | 305 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 23, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM... ► Artikel lesen | |
| 19.03. | OSR Holdings, Inc.: Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities | 547 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary... ► Artikel lesen | |
| 10.03. | OSR Holdings, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 05.03. | OSR Holdings secures 180-day extension from Nasdaq | 3 | Seeking Alpha | ||
| 05.03. | Nasdaq grants OSR Holdings extension to regain compliance | 2 | Investing.com | ||
| 05.03. | OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum | 581 | ACCESS Newswire | BELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has... ► Artikel lesen | |
| 02.02. | OSR Holdings, Inc.: CEO Statement to Shareholders | 373 | ACCESS Newswire | BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value CreationAs the compliance deadline under the minimum bid requirement of NASDAQ approaches... ► Artikel lesen | |
| 27.01. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | OSR Holdings, Inc.: OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries | 606 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment... ► Artikel lesen | |
| 14.01. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,240 | -7,84 % | PacBio & Lucid Genomics Partner to Boost Data Analysis, Stock Up | ||
| CYTOMX THERAPEUTICS | 3,536 | +0,37 % | CytomX-Aktie: sharedealsPlus-Highflyer schießt auf +1.835% Kursgewinn | Die Aktie von CytomX Therapeutics gehört weiterhin zu den spektakulärsten Turnaround-Stories im Biotech-Sektor. Seit ihrem Vorjahrestief hat sich der Kurs des sharedealsPlus-Tipps inzwischen um rund... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,127 | -100,00 % | CSE Bulletin: Name and Symbol Change - Carmanah Minerals Corp. (CARM) | Le 7 avril/April 2026
Carmanah Minerals Corp. (CARM) has announced a name and symbol change to Skull Ridge Gold Corp. (SKUL).
Shares will begin trading under the new name and symbol and with a... ► Artikel lesen | |
| CAPRICOR | 28,100 | -3,10 % | Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting | ||
| CORMEDIX | 6,306 | -3,99 % | CorMedix, Inc.: CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients | - The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 - - Study showed favorable benefit for toxicity related discontinuations... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 5,410 | -1,37 % | Minerva Neurosciences, Inc: Minerva Announces Leadership Transition | Jim O'Connor joins as Chief Business Officer and General CounselBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| REPLIMUNE | 2,098 | -4,59 % | RFK Jr. says no hand in rejecting Replimune's lead asset | ||
| VALERIO THERAPEUTICS | 0,141 | 0,00 % | Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model | Revenue: €2.6 million for the 2025 financial year, compared with €1.8 million in 2024 Operating expenses: €4.8 million, compared with €18.3 million in 2024 Creation of InVimmune... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,851 | -1,97 % | Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy | SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 23,990 | -1,68 % | Alto Neuroscience, Inc.: Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | - Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies - - Trial design and MADRS primary endpoint... ► Artikel lesen | |
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial | Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
| QIAGEN | 28,510 | -2,11 % | Qiagen: Von der Übertreibung direkt in eine Untertreibung gelaufen? | Am späten Montagabend legte Qiagen vorläufige Zahlen zum ersten Quartal vor, am gestrigen Dienstag fiel die Aktie daraufhin auf das tiefste Kursniveau seit Herbst 2019. Da die 2026er-Prognose gesenkt... ► Artikel lesen | |
| EVOTEC | 5,005 | -2,63 % | Evotec-Aktie mit +46% - kommt das Comeback? | Die Evotec-Aktie hat zuletzt kräftig zugelegt und stieg um rund +46% an. Damit hat sich das Chartbild deutlich verbessert und eine mögliche Trendwende rückt in den Fokus. Nach der dynamischen Rallye... ► Artikel lesen | |
| ERASCA | 9,320 | -5,76 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen |
OSR HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,461 Euro und damit -37,72 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.